Jump to content



Recommended Posts

  • 5 months later...
  • Replies 72
  • Created
  • Last Reply

Top Posters In This Topic

  • 2 months later...
  • 1 month later...
  • 1 month later...
  • 1 month later...

Sonic boom.


The share price was once 7 cents a long time ago. Bought in at $5.97 about 2 years ago, during price weakness. Still holding.


A leading pathology and radiology provider. Given the demographic profile, the outlook is good. Probably why it always trades at such a high P/E.


Hope the expansion in UK and Europe goes well.


I think the CEO is under-rated.





Link to comment
Share on other sites

  • 1 month later...

Sonic Healthcare net profit up 34pc to $77.5m for year

08:46, Tuesday, 23 August 2005


Sydney - Tuesday - August 23: (RWE Australian Business News) -

Sonic Healthcare Ltd (ASX code: SHL) lifted net profit 34.4 per cent to

$77.46 million in the year to June 30 from $57.63 million for the

previous year.

Core profit (pre-intangibles amortisation) rose 24.5 per cent to

$145.55 million from $116.95 million.

Earnings before interest, tax and intangibles amortisation

(EBITA) rose 32.8 per cent to $261.09 million from $196.56 million.

Revenue was up 33.3 per cent to $1.38 billion from $1.04


Basic earnings per share were 28.5c, up from 21.7c, while core

diluted EPS were 52.6c, up from 43.4c.

Final dividend has been increased from 20c to 23c, fully

franked, payable on September 19 to shareholders registered September 6.

This brings total dividend for the year to 36c, up 20 per cent.

Sonic also announced 2006 year guidance of EBITA between $300

million and $320 million on revenue of $1.6 billion to $1.67 billion.

This includes Clinical Pathology Laboratories Inc from October 1

and AIFRS impact of expensing options/shares totalling $6.3 million.




Managing director Dr Colin Goldschmidt said: "I am pleased to

report that once again Sonic Healthcare has delivered record earnings,

which have exceeded our upgraded guidance given in February 2005.

"In particular, Sonic's largest subsidiaries in both pathology

and radiology have excelled, showing impressive revenue and earnings


"This year Sonic has also reached a significant milestone, with

our 10th successive year of double-digit earnings per share growth.

"The group's more recent expansion into offshore pathology

markets in Europe - and now the USA - provides enormous growth

opportunities for the company and I am confident that we will continue

to deliver superior shareholder value into the future."

Dr Goldschmidt said the increase in dividends for the year

reflected Sonic's strong and predictable earnings and cash flows.

"The strength of the company is reflected in the progressively

incremental dividend payments to shareholders and the simultaneous

achievement of significant revenue growth, both nationally and

internationally," he said.

Shares in Sonic rose 6c to $13.41 yesterday.



Copyright ÃÆâ€â„¢ÃƒÆ’ƒÂ¢Ãƒ¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¡ÃƒÆ’â€Å¡Ãƒƒâہ¡ÃƒÆ’‚© 2005 RWE Australian Business News. All rights reserved.

Link to comment
Share on other sites

Create an account or sign in to comment

You need to be a member in order to leave a comment

Create an account

Sign up for a new account in our community. It's easy!

Register a new account

Sign in

Already have an account? Sign in here.

Sign In Now

  • Create New...